Valion Bio issues 1,287 Series A preferred shares in unregistered sale tied to $750,000 milestone payment

• Valion Bio issued 1,287 shares of Series A Preferred Stock in an unregistered sale to Statera Biopharma and Avenue Venture Opportunities Fund.
• Issuance dated July 31, 2026. Securities served as consideration for a $750,000 milestone payment tied to inventory validation for distribution and sales.
• Shares were sold in a private placement exemption under Section 4(a)(2) and/or Regulation D. Securities are restricted under Rule 144.
• Company committed to file a resale registration statement within 60 days for common stock underlying the Series A Preferred Stock.
• Conversion is capped. Holders cannot exceed a beneficial ownership limit set between 4.9% and 19.9%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006049), on August 06, 2026, and is solely responsible for the information contained therein.